How many 8-K filings has Bridgebio Pharma, Inc. filed?

Bridgebio Pharma, Inc. (BBIO) has 20 8-K (Current Event Report) filings on record, spanning Jan 2024 to May 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Bridgebio Pharma, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Bridgebio Pharma, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Bridgebio Pharma, Inc. (BBIO) — 8-K Filings

All 8-K filings from Bridgebio Pharma, Inc.. Browse 20 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (20)

8-K Filing — May 8, 2026
BridgeBio Pharma Files 8-K for Other Events & Exhibits — Oct 29, 2025 Risk: low
BridgeBio Pharma, Inc. filed an 8-K on October 29, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific
BridgeBio Pharma Files 8-K on Financials — Oct 29, 2025 Risk: low
BridgeBio Pharma, Inc. filed an 8-K on October 29, 2025, reporting on its results of operations and financial condition, and including financial statements and
BridgeBio Pharma Files 8-K Report — Oct 27, 2025 Risk: low
On October 27, 2025, BridgeBio Pharma, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specif
BridgeBio Pharma Enters Material Definitive Agreement — Jul 2, 2025 Risk: medium
On June 27, 2025, BridgeBio Pharma, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, incorporated in Dela
BridgeBio Pharma Files 8-K on Shareholder Matters — Jun 23, 2025 Risk: medium
BridgeBio Pharma, Inc. filed an 8-K on June 23, 2025, reporting events that occurred on June 20, 2025. The filing indicates material modifications to security h
BridgeBio Pharma Files 8-K on Director/Officer Changes — Mar 17, 2025 Risk: medium
On March 17, 2025, BridgeBio Pharma, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing in
BridgeBio Pharma Reports Material Agreements and Financial Updates — Feb 28, 2025 Risk: medium
On February 24, 2025, BridgeBio Pharma, Inc. entered into a material definitive agreement and also terminated a material definitive agreement. The company also
BridgeBio Pharma Files 8-K on Financials — Feb 20, 2025 Risk: low
BridgeBio Pharma, Inc. filed an 8-K on February 20, 2025, reporting on its results of operations and financial condition. The filing includes financial statemen
BridgeBio Pharma Files 8-K on Financials and Operations — Jan 13, 2025 Risk: low
BridgeBio Pharma, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also included disclosures re
BridgeBio Pharma Files 8-K for Other Events — Nov 25, 2024 Risk: low
BridgeBio Pharma, Inc. filed an 8-K on November 22, 2024, to report other events and financial statements. The filing does not detail specific transactions or f
BridgeBio Pharma Files 8-K — Sep 11, 2024 Risk: low
BridgeBio Pharma, Inc. filed an 8-K on September 10, 2024, reporting an "Other Event." The filing does not contain specific details about the event, financial f
BridgeBio Pharma Enters Material Definitive Agreement — Aug 21, 2024 Risk: medium
BridgeBio Pharma, Inc. announced on August 16, 2024, that it has entered into a material definitive agreement. The company, incorporated in Delaware, filed an 8
BridgeBio Pharma Elects New Directors, Discloses Executive Compensation — Jul 23, 2024 Risk: low
BridgeBio Pharma, Inc. announced on July 23, 2024, a change in its board of directors, with Dr. Philip P. Brooks and Dr. Jonathan M. Fleming being elected as Cl
BridgeBio Pharma Files 8-K on Shareholder Votes and Exhibits — Jun 24, 2024 Risk: low
BridgeBio Pharma, Inc. filed an 8-K on June 24, 2024, reporting on matters submitted to a vote of security holders and financial statements/exhibits. The earlie
BridgeBio Pharma Files 8-K Report — Jun 6, 2024 Risk: low
On June 4, 2024, BridgeBio Pharma, Inc. filed an 8-K report detailing an "Other Events" filing. The report does not contain specific financial figures or new ma
BridgeBio Pharma Files 8-K: Material Agreement Announced — Mar 6, 2024 Risk: medium
BridgeBio Pharma, Inc. announced on March 5, 2024, that it entered into a material definitive agreement. The company also reported other events and filed financ
BridgeBio Pharma Enters Material Definitive Agreement — Mar 4, 2024 Risk: medium
On March 1, 2024, BridgeBio Pharma, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement, such as t
BridgeBio Pharma: Material Agreement Entered & Terminated, New Obligation — Jan 18, 2024
BridgeBio Pharma, Inc. filed an 8-K on January 18, 2024, reporting events from January 17, 2024, concerning the entry into and termination of a material definit
BridgeBio Pharma Files 8-K for 'Other Events,' Rule 425 Comms — Jan 8, 2024
BridgeBio Pharma, Inc. filed an 8-K on January 8, 2024, to report "Other Events" and "Financial Statements and Exhibits." This filing indicates that the company

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX